Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-L1 expression investigation in chemotherapy-naive unresectable esophageal cancer patients treated with tislelizumab
jRCT1030250219Recruiting
- Sponsor
- BeOne Medicines
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of tislelizumab in esophageal cancer, sponsored by BeOne Medicines. Started Jul 2025; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on jRCT1030250219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1030250219.